Back to search results

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

Abroad (travel likely)RecruitingPHASE2

Conditions

Amyotrophic Lateral Sclerosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • 062, Phoenix, Arizona, United States

  • 278, San Francisco, California, United States

  • 287, Neptune City, New Jersey, United States

  • 353, New York, New York, United States

  • 108, Leuven, Belgium

  • 425, Hamilton, Ontario, Canada

  • 273, Montreal, Quebec, Canada

  • 422, Bron, France

  • 258, Lille, France

  • 257, Limoges, France

  • 261, Marseille, France

  • 423, Montpellier, France

  • 259, Nice, France

  • 262, Paris, France

  • 256, Tours, France

  • 255, Berlin, Germany

  • 270, Bonn, Germany

  • 268, Dresden, Germany

  • 260, Hanover, Germany

  • 265, Jena, Germany

  • 386, München, Germany

  • 267, Rostock, Germany

  • 269, Ulm, Germany

  • 253, Dublin, Ireland

  • 264, Utrecht, Netherlands

  • 283, Bydgoszcz, Poland

  • 385, Krakow, Poland

  • 254, Warsaw, Poland

  • 274, Warsaw, Poland

  • 302, Barcelona, Spain

  • 115, Barcelona, Spain

  • 303, Madrid, Spain

  • 282, Málaga, Spain

  • 194, Valencia, Spain

  • 263, Stoke-on-Trent, United Kingdom

Study leads

  • Sophia Majeed, PharmD, PhD

    Study Director

    Corcept Therapeutics Incorporated

View source on ClinicalTrials.gov(opens in a new tab)